U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07492316) titled 'RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)' on March 19.
Brief Summary: The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Recurrent Medulloblastoma
Intervention:
BIOLOGICAL: Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid ...